Ocular Therapeutix® to Host Investor Day on June 13, 2024
05 Giugno 2024 - 1:30PM
Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a
biopharmaceutical company committed to enhancing people’s vision
and quality of life through the development and commercialization
of innovative therapies for wet age-related macular degeneration
(wet AMD), diabetic retinopathy, and other diseases and conditions
of the eye, will host an Investor Day on Thursday, June 13, 2024.
The in-person event with virtual access will begin at 2:00 PM ET.
To register, click here.
The Investor Day will feature prominent retinal disease key
opinion leaders (KOLs) Baruch D. Kuppermann, MD, PhD (University of
California, Irvine) and Dilsher S. Dhoot, MD (California Retina
Consultants). The event will include presentations from senior
Company leaders providing:
- An overview of the Company’s updated corporate strategy,
pipeline priorities, and future development plans;
- A review of Ocular’s clinical program for AXPAXLI in the
treatment of wet AMD, including a progress update for the ongoing
SOL-1 study; and
- An update and discussion of the Phase 1 HELIOS data for AXPAXLI
in non-proliferative diabetic retinopathy (NPDR).
Ocular’s Investor Day will also include KOL roundtable
discussions followed by a live Q&A session. In-person attendees
are invited to join Ocular leadership and the participating KOLs
for a networking reception to conclude the event.
A live webcast of the presentation will be available under
"Events and Presentations" in the Investors section of the
Company’s website at investors.ocutx.com. A replay of the webcast
will be archived for at least 30 days following the
presentation.
About Baruch D. Kuppermann, MD, PhDBaruch D.
Kuppermann, MD, PhD, is the Steinert Endowed Professor, Chair of
the Department of Ophthalmology, and Director of the Gavin Herbert
Eye Institute at the University of California, Irvine (UC Irvine).
He also holds a joint appointment with the Department of Biomedical
Engineering at UC Irvine. After completing his PhD in neuroscience
at the California Institute of Technology, Dr. Kuppermann earned
his medical degree at the University of Miami and completed
fellowships in retina at both St. Joseph’s Medical Center in
Baltimore, under Drs Ron Michels and Bert Glaser, and at the
University of California, San Diego.
Dr. Kuppermann is actively involved in clinical research, having
served as Principal Investigator in many trials evaluating new
drugs and technologies for the treatment of age-related macular
degeneration, diabetic retinopathy, retinal vein occlusion,
retinitis pigmentosa, and other diseases of the posterior segment
of the eye. He also has a laboratory at UC Irvine that evaluates
the toxicology of drugs on the retina as well as studying the
mitochondrial genetics of age-related macular degeneration. He has
published over 300 peer-reviewed articles in medical literature,
and over 70 book chapters. Dr. Kuppermann is a peer reviewer for
leading journals in ophthalmology, retina, and medicine, including
the American Journal of Ophthalmology, Archives of Ophthalmology,
Lancet, Ophthalmology, and Retina, and serves on the Editorial
Board of the journal Retina.
About Dilsher S. Dhoot, MDDilsher S. Dhoot, MD
received his undergraduate degree with Honors from the University
of California, Berkeley and his medical degree at Oregon Health
Science University in Portland, Oregon. Dr. Dhoot is a
Board-Certified Ophthalmologist. He completed his residency in
ophthalmology at the Casey Eye Institute and a fellowship in
vitreoretinal surgery at the Cleveland Clinic, Cole Eye
Institute.
Dr. Dhoot has been a primary investigator in numerous clinical
research trials for the treatment of age-related macular
degeneration, retinal vein occlusion, and diabetic retinopathy. He
has received numerous awards during his career, including the
Senior Honor Award from the American Society of Retina Specialists
and the American Academy of Ophthalmology Achievement Award. Dr.
Dhoot has presented his research at international conferences and
published numerous book chapters and articles in journals including
Ophthalmology, the British Journal of Ophthalmology, Retina, Eye,
and Ophthalmic Surgery, Lasers & Imaging. He currently serves
as a section editor for the Retina Times and is also a peer
reviewer for several journals.
About Ocular Therapeutix, Inc.Ocular
Therapeutix, Inc. is a biopharmaceutical company committed to
enhancing people’s vision and quality of life through the
development and commercialization of innovative therapies for wet
age-related macular degeneration (wet AMD), diabetic retinopathy
(DR), and other diseases and conditions of the
eye. AXPAXLI™ (axitinib intravitreal implant, also known
as OTX-TKI), Ocular’s product candidate for retinal disease, is
based on its ELUTYX™ proprietary bioresorbable hydrogel-based
formulation technology. AXPAXLI is currently in a Phase 3 clinical
trial for wet AMD. The clinical portfolio also
includes PAXTRAVA™ (travoprost intracameral implant, also
known as OTX-TIC), currently in a Phase 2 clinical trial for the
treatment of open-angle glaucoma or ocular hypertension.
Ocular’s expertise in the formulation, development, and
commercialization of innovative therapies of the eye and the ELUTYX
platform supported the development and launch of its first
commercial drug product, DEXTENZA®, an FDA-approved
corticosteroid for the treatment of ocular inflammation and pain
following ophthalmic surgery and ocular itching associated with
allergic conjunctivitis. ELUTYX is also the foundation for two
other clinical-stage assets, OTX-CSI (cyclosporine
intracanalicular insert) for the chronic treatment of dry eye
disease and OTX-DED (dexamethasone intracanalicular
insert) for the short-term treatment of the signs and symptoms of
dry eye disease, as well as several preclinical programs.
Follow us on our website, LinkedIn, or X.
DEXTENZA® and Ocular Therapeutix® are registered trademarks
of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, and
ELUTYX™ are trademarks of Ocular Therapeutix, Inc.
Investors & MediaOcular Therapeutix,
Inc.Bill SlatteryVice President, Investor
Relationsbslattery@ocutx.com
Grafico Azioni Ocular Therapeutix (NASDAQ:OCUL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Ocular Therapeutix (NASDAQ:OCUL)
Storico
Da Lug 2023 a Lug 2024